Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of P1101 vs anagrelide as second-line therapy for essential thrombocythemia
ChiCTR2000036395Phase 3Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ropeginterferon alfa-2b in thrombocythemia (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Peripheral blood cell count response. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
thrombocythemia
Beyond the preview
Go deeper on ChiCTR2000036395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036395.